Event context and why HealthEquity is on investors’ radar

HealthEquity (HQY) is drawing fresh attention after recent share price moves, with the stock up 9% over the past month and 8% in the past 3 months, prompting investors to reassess its fundamentals.

Those recent share price gains sit against a mixed backdrop, with the 1-year total shareholder return down 12.23% but the 3-year total shareholder return up 49.76%. This suggests longer term holders have still seen meaningful value creation while shorter term momentum has only recently picked up.

If HealthEquity’s move has you thinking more broadly about the sector, it could be a good time to scan for other healthcare-focused AI opportunities using the 34 healthcare AI stocks

With HealthEquity posting steady annual revenue and net income growth, and the stock trading below some valuation estimates, the key question is whether the recent rebound is an entry point or if markets already price in future growth.

Most Popular Narrative: 25% Undervalued

HealthEquity’s most followed narrative pegs fair value at $112.88, well above the last close of $84.84, which puts a spotlight on the growth assumptions behind that gap.

The recent regulatory expansion, allowing direct primary care, pre-deductible telehealth, and millions of new ACA bronze/catastrophic plan members to qualify for HSAs, creates the largest addressable market increase in two decades and is expected to accelerate new account openings and AUM growth, meaningfully boosting future revenue.

Want to see what sits under that fair value estimate? The narrative leans on steady revenue gains, rising margins and a richer earnings base by the end of the decade.

Result: Fair Value of $112.88 (UNDERVALUED)

However, the story can change quickly if a weaker labor market limits new HSA accounts or if lower interest rates hit custodial cash yields and squeeze margins.

Another view on valuation: earnings multiples paint a tougher picture

The narrative and analyst targets lean on future cash flows and long term growth, but today’s P/E ratio of 33.3x tells a different story. It sits above the US Healthcare industry average of 22.1x and above a fair ratio estimate of 25.2x, which points to less room for error if growth or margins disappoint.

For a clearer sense of how that earnings multiple stacks up against peers and where the market could move if sentiment cools, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

With mixed signals on valuation and sentiment, it helps to see the data directly and move fast to frame your own opinion before consensus shifts. To understand what the market currently views as the key positives, review the 4 key rewards.

Ready for more investment ideas?

If you stop with just one stock, you risk missing opportunities that better match your goals. Take a few minutes to scan wider with the Simply Wall St screener.

• Spot potential value with stronger fundamentals by checking companies in the 49 high quality undervalued stocks.
• Prioritise resilience first and review stocks screened for 71 resilient stocks with low risk scores.
• Hunt for under-the-radar opportunities in the screener containing 21 high quality undiscovered gems before they attract broader attention.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.